Etripamil

Investigational Therapeutic for
Episodic Cardiovascular Conditions

We are developing our investigational product etripamil, a novel calcium channel blocker in the form of a nasal spray, for the acute treatment of patients with PSVT and other episodic cardiovascular conditions, including atrial fibrillation and angina, wherever they occur.

Milestone at its founding sought to create new chemical entities as analogs of known molecular classes with clinically validated mechanisms of action. Our goal remains to preserve the beneficial pharmacology of existing molecules while altering their pharmacokinetic profile with focused medicinal chemistry to produce drugs that are fast-acting and rapidly inactivated in the blood to minimize potential side effects.

As a result, we are developing etripamil, a novel calcium channel blocker.

We are currently conducting a comprehensive development program for etripamil designed to explore the following clinical outcomes:

  • Administration: Etripamil is designed to be self-administered by patients via a nasal spray device.
  • Absorption: Etripamil is designed to be absorbed into the bloodstream in less than 10 minutes through the inner lining of the nose, which has many blood vessels.
  • Action: Etripamil is designed to act upon the desired target within 30-45 minutes with the goal of reducing long-term side effects that may occur with chronic drug therapy.

Currently, etripamil is in Phase 3 development for the acute treatment of PSVT. We are also investigating etripamil for patients living with atrial fibrillation and angina.

We believe that the following qualities of etripamil make it a better treatment for certain transient cardiovascular conditions than current standards of care

We believe that the following qualities of etripamil make it a better treatment for certain transient cardiovascular conditions than current standards of care

Administration

Absorption

Action